Genfit SA

GENFIT to Present Latest ACLF Research at EASL Congress™ 2024

29 май 2024 16:10:00 Источник Nasdaq GlobeNewswire

GENFIT: May 22, 2024 Combined Shareholders Meeting Results

22 май 2024 12:05:00 Источник Nasdaq GlobeNewswire

GENFIT Reports First Quarter 2024 Financial Information

14 май 2024 16:10:00 Источник Nasdaq GlobeNewswire

GENFIT: Publication of the 2024 Extra-Financial Performance Report (fiscal year 2023)

25 апр 2024 16:10:00 Источник Nasdaq GlobeNewswire

GENFIT Annual Combined General Meeting of May 22, 2024 — Availability of Preparatory Documents

15 апр 2024 16:10:00 Источник Nasdaq GlobeNewswire

GENFIT Announces Publication of the 2023 Universal Registration Document and the 2023 Annual Report on Form 20-F

05 апр 2024 14:00:00 Источник Nasdaq GlobeNewswire

GENFIT Reports Full-Year 2023 Financial Results and Provides Corporate Update

04 апр 2024 16:10:00 Источник Nasdaq GlobeNewswire

GENFIT Announces Revenues and Cash Position as of December 31, 2023

29 фев 2024 16:10:00 Источник Nasdaq GlobeNewswire

GENFIT Announces 2024 Financial Calendar  

15 янв 2024 16:10:00 Источник Nasdaq GlobeNewswire

GENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial

11 янв 2024 16:10:00 Источник Nasdaq GlobeNewswire

GENFIT Updates 2024 Outlook Following Acceptance of Elafibranor Filings in Primary Biliary Cholangitis (PBC)

08 дек 2023 01:55:00 Источник Nasdaq GlobeNewswire

Ipsen confirms U.S. FDA grants priority review for New Drug Application for elafibranor for the treatment of rare cholestatic liver disease, PBC

07 дек 2023 05:15:01 Источник Nasdaq GlobeNewswire

GENFIT Announces Publication in the Journal of Hepatology on the Accurate Performance of NIS2+™ as a Screening Tool for the Enrollment of Patients in MASH Clinical Trials

06 дек 2023 11:30:00 Источник Nasdaq GlobeNewswire

GENFIT Highlights ACLF Development Strategy at “ACLF Day” during AASLD The Liver Meeting® 2023

16 ноя 2023 16:10:00 Источник Nasdaq GlobeNewswire

GENFIT: Results from Ipsen’s ELATIVE® pivotal Phase III trial of elafibranor in PBC presented as late breaking data at AASLD congress and published in New England Journal of Medicine

13 ноя 2023 16:30:00 Источник Nasdaq GlobeNewswire

GENFIT Reports Third Quarter 2023 Financial Information

09 ноя 2023 16:10:00 Источник Nasdaq GlobeNewswire

GENFIT to Present Update on Scientific and Corporate Progress at The Liver Meeting® 2023

02 ноя 2023 17:10:00 Источник Nasdaq GlobeNewswire

GENFIT Announces Publication in Nature Medicine Confirming the Performance of its NASH Diagnostic Technology  

26 сен 2023 16:10:00 Источник Nasdaq GlobeNewswire

GENFIT Reports First Half-Year 2023 Financial Results and Provides Corporate Update

20 сен 2023 16:10:00 Источник Nasdaq GlobeNewswire

GENFIT to Participate in Upcoming Investor Conferences

05 сен 2023 16:10:00 Источник Nasdaq GlobeNewswire